

11 April 2017

## **ePAT introduces first version iOS App at Pain Society conference**

### **Highlights:**

- **ePAT to participate in leading pain specialist event**
- **Demonstrating first version iOS App to potential end-users for feedback**
- **Presenting clinical paper at symposium**

ePAT Technologies (ASX:EPT, 'ePAT' or the 'Company') is pleased to announce the Company is continuing to increase its industry recognition within the Australian medical sector, demonstrating its revolutionary pain detection technology to a series of highly-qualified experts.

The Company is taking an active role at the Australian Pain Society's 37th annual scientific meeting, which will host 800 pain specialists during the 9-12<sup>th</sup> April 2017.

The conference attendees represent a prime target audience for end-users of the ePAT app.

The Australian Pain Society is a major industry body aiming to relieve pain through advancements in clinical practice, education and research. The conference is expected to be the only forum in Australia offering multidisciplinary insights into pain management from a variety of medical, nursing and allied health perspectives.

ePAT will be exhibiting at the Australian Pain Society meeting, permitting face-to-face interaction with attending industry experts.

The Company is demonstrating its first version of the iOS (Apple) app. This version will allow ePAT to provide live demonstrations of its technology at the conference. This will not only permit ePAT to demonstrate proof-of-concept, but also receive valuable and immediate industry feedback.

ePAT is also presenting a paper at the main plenary conference session, further boosting exposure of its technology.

The Company will be presenting on a paper titled "The Reliability of the ePAT tool in residents with moderate to severe dementia". The presentation will summarise the work completed on the ePAT app to date and will also highlight the accuracy of the pain detection technology.

The information in this presentation was released to the market on 6 March 2017.

"ePAT continues to gather pace as we continue to develop and market our revolutionary technology," ePAT managing director, Mr Philip Daffas. "We're pleased to be taking such an active part at the Australian Pain Society conference, which presents a major opportunity to target industry professionals, who we envision will be active users of our app," he said.

**About ePAT:**

ePAT Technologies Limited is an Australian based company which is developing mobile medical applications that are intended to provide pain assessment for individuals that are unable to communicate verbally with their carers.

**The ePAT business:**

The ePAT business has evolved from research undertaken by Curtin University in Western Australia over the past 3 years. ePAT now owns the intellectual property resulting from Curtin University's research on the ePAT Apps.

ePAT's technology, a mobile application (**ePAT App**), uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score.

Due to its ease of use and its reproducibility, it is intended that the ePAT App will be able to be used in the first instance to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management provided to the person.

The ePAT App is being developed and will be rolled out globally in two phases: first, the ePAT App for Dementia for persons who have lost the ability to communicate with their carers, and the second, the ePAT App for Children who have not yet learnt to speak.

For further information contact:

Ian Hobson  
Company Secretary  
Tel: +61 8 9388 8290

Philip Daffas  
Managing Director  
Tel: +61 406 537 235